By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Selecta Biosciences, Inc. 

480 Arsenal Street
Building One
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-923-1400 Fax: 617-924-3454


Company News
3SBio Inc. (SSRX) Exclusively Licenses Pegsiticase (Uricase PEG-20) To Selecta Biosciences, Inc. To Develop Drug Candidate To Treat Gout 6/18/2014 9:20:48 AM
Selecta Biosciences, Inc. Accelerates Immune Tolerance Therapeutics And Announces New Product Candidate, SEL-212, For Refractory And Tophaceous Gout 6/17/2014 12:56:44 PM
Selecta Biosciences, Inc. Enters Into Exclusive License Agreement With 3SBio Inc. (SSRX) To Develop Drug Candidate To Treat Gout 6/17/2014 11:29:08 AM
Selecta Biosciences, Inc. To Accelerate Program For Novel Dual Action Vaccine For Malaria 6/17/2014 10:11:42 AM
Selecta Biosciences, Inc. Announces Allowance Of The First In A Series Of Patents On The Induction Of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies 12/9/2013 9:15:55 AM
Selecta Biosciences, Inc. Announces Successful Pre-Clinical Study Of SEL-201 As An Antigen-Specific Immune Tolerance Treatment For Patients Receiving Factor VIII Therapy 12/9/2013 9:12:04 AM
Selecta Biosciences, Inc. Distinguished as World Economic Forum Technology Pioneer 2014 8/27/2013 10:17:34 AM
Sanofi (France) (SAN.PA) Deal Could Net Selecta Biosciences, Inc. $900 Million 11/28/2012 6:42:44 AM
Selecta Biosciences, Inc. Receives 2012 Edison Award’s Gold Medal for Best Pharmaceutical Product Innovation 5/9/2012 10:27:33 AM
Selecta Biosciences, Inc. Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention 11/21/2011 8:36:09 AM